Novartis will still file patent applications in IndiaNovartis India will still submit patent applications in India despite the country's Supreme Court decision denying the drugmaker a patent for cancer treatment Glivec, Vice Chairman Ranjit Shahani said. The drugmaker also plans to keep investing in the country with caution, Shahani added.Reuters
(4/1)

Share:

PhRMA blasts Indian court's ruling against drug patentThe Pharmaceutical Research and Manufacturers of America rebuked India's Supreme Court for refusing to grant Novartis patent protection on its cancer medicine Glivec. The ruling is "another example of what I would characterize as a deteriorating innovation environment in India," said Chip Davis, PhRMA's executive vice president of advocacy. "[I]t is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide," PhRMA CEO John J. Castellani said.The Hill/Healthwatch blog
(4/1),The New York Times (tiered subscription model)
(4/1),Reuters
(4/1)

Embrace Disruptive InnovationTraditional business is constantly being impacted by overwhelming and sudden shifts in the marketplace. This new normal is "disruptive innovation". Read this white paper to learn what disruptive innovation is and how your company can use cloud ERP to stay in the game. Download the white paper >

ADVERTISEMENT

Food & Dietary Supplements

Producer of baking mixes pulls products for milk useHeartland Gourmet has decided to recall cookie mix products, which were distributed in seven states, due to undeclared use of milk. Affected products include 16 ounce-packs of Gluten Free Chocolate Chip Cookie Mix and Gluten Free Double Chocolate Cookie Mix, as well as 15.4-ounce-packs of Gluten Free Pizza Crust Mix.Food Business Review
(4/1)

Share:

Medical Devices

Appeals court rules in favor of Abbott in patent suitA federal appeals court ruled in favor of Abbott in a patent infringement case with Cordis, a Johnson & Johnson unit, regarding drug-eluting stent technology. The court upheld a lower court's decision to nullify two subpoenas sought by Cordis to find proof of its allegation that Abbott copied the stent patents.MassDevice.com (Boston)
(4/1)

FDA: Nicotine gum, patch makers can change smoking cessation labelsThe FDA announced its decision to allow makers of nicotine gum, patches and lozenges to change labels recommending consumers quit smoking when using nicotine replacement products. Also, the FDA said manufacturers can change labels to say that the products can be used for longer time periods than previously indicated. The agency expects the changes to encourage more consumers to "use these products effectively for smoking cessation and that tobacco dependence will decline," said FDA Commissioner Margaret Hamburg.The Washington Post/The Associated Press
(4/1)

Share:

FDLI Items

Don't miss FDLI's spring introductory courses on drug or medical device law and regulationFDLI's industry standard two-day introductory courses are important programs we have been offering for more than 20 years - teaching thousands to think like seasoned professionals. Whether you are a new professional in the medical device or pharmaceutical industry or a seasoned regulatory affairs or legal professional needing a refresher on current FDA regulatory developments, you will benefit from attending our in-depth, interactive courses. FDLI's introductory courses can help you and your organization understand FDA regulations, support your efforts to get products approved and know when FDA is likely to allege violations of the law.

Join us at FDLI’s Annual Conference for one of our most popular plenary sessions, as academic experts review the “Top 20 Cases in Food and Drug Law in 2012 and Cases to Watch in 2013.” Drawing from FDLI’s newest edition of Top 20 Cases, food and drug law professors will discuss the legal and practical impact—on the entire food and drug law community—of 2012’s most sweeping cases and highlight cases to watch in 2013: